Grace L. Su, MD, FAASLD is the H. Marvin Pollard Collegiate Professor of Gastroenterology III and Professor of Medicine and Surgery at the University of Michigan Medical School. After completing her undergraduate degree from Yale University and M.D. from the University of Chicago, she pursued her residency and fellowship at the University of Pittsburgh.

As a physician scientist, Dr. Su has a long history of performing clinical and translational research in the area of chronic liver disease and cirrhosis. She is Director of the Morphomics Analysis Group at the University of Michigan, a multidisciplinary collaborative of physicians, biostatisticians and engineers developing methods for analyzing medical imaging. Their work has evolved into analytic morphomics, an innovative high-throughput, highly automated, anatomically indexed platform that measures body composition and organ condition. By linking imaging features to clinical outcomes, they have been able develop highly accurate non-invasive methods for the diagnosis and prognosis of patients with liver disease as well as hepatocellular carcinoma (HCC).

Disclosures of Potential Conflicts of Interest
Dr. Su has nothing to disclose.

W. Ray Kim, MD, MBA, FAASLD, Professor of Medicine at Mayo Clinic Arizona, Scottsdale, AZ

Dr. Kim received his MD degree from Seoul National University and his MBA from the University of Pennsylvania. Following his medicine residency at Seoul National University and the University of Arkansas, he underwent gastroenterology and hepatology fellowship training at Mayo Clinic in Minnesota.  Subsequently, Ray joined the faculty of the Mayo College of Medicine, where he established his research in prognostication in patients with chronic liver disease.  He is best known for his work in developing, validating and refining the Model for End-stage Liver Disease (MELD) score.

In 2013, he was recruited to Stanford University to lead the Division of Gastroenterology and Hepatology.  Under his leadership, the Division prospered with a significant growth in the breadth and depth of faculty and their expertise, innovative educational programs for the GI, liver and other advanced fellowships, excellence in scientific scholarship and supportive community with emphasis on mentorship and individual growth.

After serving as the GI Chief at Stanford for nearly 11 years, he is returning to Mayo to create the Center for Policy and Outcomes Research in Transplantation (CPORT) based in the Arizona campus.

Vijay H. Shah, MD, FAASLD received his undergraduate, medical, and clinical medicine training at Northwestern University. He obtained advanced clinical and research postdoctoral fellowship training in hepatology and portal hypertension at Yale University.

He has maintained an NIH-funded program at Mayo Clinic for almost 25 years which focuses broadly on alcohol-associated liver disease, cirrhosis, portal hypertension and its complications with over 250 peer-reviewed publications in prestigious journals such as Journal of Clinical Investigation, Nature, Proceedings of National Academy of Science, New England Journal of Medicine and others.

Dr. Shah is a member of the prestigious American Society of Clinical Investigation and the American Associations of Physicians. Presently, Dr. Shah serves as the Charles M. Gatton and Mayo Distinguished Investigator Chair of Medicine at Mayo Clinic.

Disclosures of Potential Conflicts of Interest
Dr. Vijay H. Shah is an Advisory Board Member for Azaka Bioscience Ltd. and Surrozen Inc., provides consulting services for Ambys Medicine and Durect Corporation, and has a know-how arrangement with Generon Shanghai processed through Mayo Clinic.

Dr. Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He has been an internationally recognized researcher in the areas of HCV virology and pathogenesis. He directs an NIH Cooperative Center for Human Immunology centered on HCV, and is co-PI of the Harvard HBV Consortium of the NIH HBV Research Network. He is contact PI of his Divisional T32 Training Grant, and holds several NIH R01 grants and an NIH K24 Mentorship Award.

He was recently Associate Editor of HEPATOLOGY and has previously served as a Councilor at Large for the AASLD. He has also served as co-Chair of the AASLD/IDSA HCV Guidance panel which is charged with issuing treatment recommendations for hepatitis C. He has authored more than 300 original articles, reviews, and editorials.

Disclosures of Potential Conflicts of Interest
Dr. Raymond T. Chung has received grant support from Abbvie, Gilead, Merck, Janssen, Bristol-Myers Squibb, Roche, and Boehringer Ingelheim. He serves on the data safety monitoring board for Alnylam.